APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Injectable Anticoagulants

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Injectable Anticoagulants Market Outlook and Growth Opportunities 2026

Report ID 174002990429 December 2025199 pages

Choose your research edition.

Industry ResearchInjectable Anticoagulants Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Injectable Anticoagulants Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Injectable Anticoagulants Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Injectable Anticoagulants Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Injectable Anticoagulants Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Injectable Anticoagulants market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Injectable Anticoagulants is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Injectable Anticoagulants is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Injectable Anticoagulants is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Injectable Anticoagulants market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Injectable Anticoagulants market include Sanofi, King-friend, Pfizer, Hepalink, CSBIO, Genentech (Roche), Boehringer Ingelheim, Aspen and Amphastar Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Injectable Anticoagulants market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Injectable Anticoagulants and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Injectable Anticoagulants revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Injectable Anticoagulants market.

Injectable Anticoagulants Segment by Company

Sanofi

King-friend

Pfizer

Hepalink

CSBIO

Genentech (Roche)

Boehringer Ingelheim

Aspen

Amphastar Pharmaceuticals

Injectable Anticoagulants Segment by Type

LMWH

Fibrinolytics

Unfractionated Heparin

Others

Injectable Anticoagulants Segment by Application

ACS/MI

VTE

AF

Others

Injectable Anticoagulants Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Injectable Anticoagulants status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Injectable Anticoagulants key companies, revenue, market share, and recent developments.

3. To split the Injectable Anticoagulants breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Injectable Anticoagulants market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Injectable Anticoagulants significant trends, drivers, influence factors in global and regions.

6. To analyze Injectable Anticoagulants competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Injectable Anticoagulants market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Injectable Anticoagulants and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Injectable Anticoagulants.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Injectable Anticoagulants industry.

Chapter 3: Detailed analysis of Injectable Anticoagulants company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Injectable Anticoagulants in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Injectable Anticoagulants in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Injectable Anticoagulants Industry Trends Table 2. Injectable Anticoagulants Industry Drivers Table 3. Injectable Anticoagulants Industry Opportunities and Challenges Table 4. Injectable Anticoagulants Industry Restraints Table 5. Global Injectable Anticoagulants Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Injectable Anticoagulants Revenue Share by Company (2021-2026) Table 7. Global Injectable Anticoagulants Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Injectable Anticoagulants Key Company Manufacturing Base & Headquarters Table 9. Global Injectable Anticoagulants Company, Product Type & Application Table 10. Global Injectable Anticoagulants Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Injectable Anticoagulants by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of LMWH Table 15. Significant Companies of Fibrinolytics Table 16. Significant Companies of Unfractionated Heparin Table 17. Significant Companies of Others Table 18. Global Injectable Anticoagulants Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Injectable Anticoagulants Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Injectable Anticoagulants Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Injectable Anticoagulants Sales Value Share by Type (2021-2026) Table 22. Global Injectable Anticoagulants Sales Value Share by Type (2027-2032) Table 23. Significant Companies of ACS/MI Table 24. Significant Companies of VTE Table 25. Significant Companies of AF Table 26. Significant Companies of Others Table 27. Global Injectable Anticoagulants Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Injectable Anticoagulants Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Injectable Anticoagulants Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Injectable Anticoagulants Sales Value Share by Application (2021-2026) Table 31. Global Injectable Anticoagulants Sales Value Share by Application (2027-2032) Table 32. Global Injectable Anticoagulants Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Injectable Anticoagulants Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Injectable Anticoagulants Sales Value Share by Region (2021-2026) Table 35. Global Injectable Anticoagulants Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Injectable Anticoagulants Sales Value Share by Region (2027-2032) Table 37. Global Injectable Anticoagulants Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Injectable Anticoagulants Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Injectable Anticoagulants Sales Value Market Share by Country (2021-2026) Table 40. Global Injectable Anticoagulants Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Injectable Anticoagulants Sales Value Market Share by Country (2027-2032) Table 42. Sanofi Company Information Table 43. Sanofi Business Overview Table 44. Sanofi Injectable Anticoagulants Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Sanofi Injectable Anticoagulants Product Portfolio Table 46. Sanofi Recent Development Table 47. King-friend Company Information Table 48. King-friend Business Overview Table 49. King-friend Injectable Anticoagulants Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. King-friend Injectable Anticoagulants Product Portfolio Table 51. King-friend Recent Development Table 52. Pfizer Company Information Table 53. Pfizer Business Overview Table 54. Pfizer Injectable Anticoagulants Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Pfizer Injectable Anticoagulants Product Portfolio Table 56. Pfizer Recent Development Table 57. Hepalink Company Information Table 58. Hepalink Business Overview Table 59. Hepalink Injectable Anticoagulants Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Hepalink Injectable Anticoagulants Product Portfolio Table 61. Hepalink Recent Development Table 62. CSBIO Company Information Table 63. CSBIO Business Overview Table 64. CSBIO Injectable Anticoagulants Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. CSBIO Injectable Anticoagulants Product Portfolio Table 66. CSBIO Recent Development Table 67. Genentech (Roche) Company Information Table 68. Genentech (Roche) Business Overview Table 69. Genentech (Roche) Injectable Anticoagulants Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Genentech (Roche) Injectable Anticoagulants Product Portfolio Table 71. Genentech (Roche) Recent Development Table 72. Boehringer Ingelheim Company Information Table 73. Boehringer Ingelheim Business Overview Table 74. Boehringer Ingelheim Injectable Anticoagulants Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Boehringer Ingelheim Injectable Anticoagulants Product Portfolio Table 76. Boehringer Ingelheim Recent Development Table 77. Aspen Company Information Table 78. Aspen Business Overview Table 79. Aspen Injectable Anticoagulants Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Aspen Injectable Anticoagulants Product Portfolio Table 81. Aspen Recent Development Table 82. Amphastar Pharmaceuticals Company Information Table 83. Amphastar Pharmaceuticals Business Overview Table 84. Amphastar Pharmaceuticals Injectable Anticoagulants Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Amphastar Pharmaceuticals Injectable Anticoagulants Product Portfolio Table 86. Amphastar Pharmaceuticals Recent Development Table 87. Research Programs/Design for This Report Table 88. Authors List of This Report Table 89. Secondary Sources Table 90. Primary Sources List of Figures Figure 1. Injectable Anticoagulants Product Image Figure 2. Global Injectable Anticoagulants Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Injectable Anticoagulants Market Size (2021-2032) & (US$ Million) Figure 4. Global Injectable Anticoagulants Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. LMWH Image Figure 8. Fibrinolytics Image Figure 9. Unfractionated Heparin Image Figure 10. Others Image Figure 11. Global Injectable Anticoagulants Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Injectable Anticoagulants Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Injectable Anticoagulants Sales Value Share by Type (2021-2032) Figure 14. ACS/MI Image Figure 15. VTE Image Figure 16. AF Image Figure 17. Others Image Figure 18. Global Injectable Anticoagulants Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Injectable Anticoagulants Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Injectable Anticoagulants Sales Value Share by Application (2021-2032) Figure 21. Global Injectable Anticoagulants Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Injectable Anticoagulants Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Injectable Anticoagulants Sales Value (2021-2032) & (US$ Million) Figure 24. North America Injectable Anticoagulants Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Injectable Anticoagulants Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Injectable Anticoagulants Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Injectable Anticoagulants Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Injectable Anticoagulants Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Injectable Anticoagulants Sales Value (2021-2032) & (US$ Million) Figure 30. South America Injectable Anticoagulants Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Injectable Anticoagulants Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Injectable Anticoagulants Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Injectable Anticoagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • LMWH
  • Fibrinolytics
  • Unfractionated Heparin
  • Others
Applications
  • ACS/MI
  • VTE
  • AF
  • Others
Companies covered
  • Sanofi
  • King-friend
  • Pfizer
  • Hepalink
  • CSBIO
  • Genentech (Roche)
  • Boehringer Ingelheim
  • Aspen
  • Amphastar Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Injectable Anticoagulants Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Injectable Anticoagulants Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Injectable Anticoagulants Market Dynamics
  1. 2.1 Injectable Anticoagulants Industry Trends
  2. 2.2 Injectable Anticoagulants Industry Drivers
  3. 2.3 Injectable Anticoagulants Industry Opportunities and Challenges
  4. 2.4 Injectable Anticoagulants Industry Restraints
3 Injectable Anticoagulants Market by Company
  1. 3.1 Global Injectable Anticoagulants Company Revenue Ranking in 2025
  2. 3.2 Global Injectable Anticoagulants Revenue by Company (2021-2026)
  3. 3.3 Global Injectable Anticoagulants Company Ranking (2024-2026)
  4. 3.4 Global Injectable Anticoagulants Company Manufacturing Base and Headquarters
  5. 3.5 Global Injectable Anticoagulants Company Product Type and Application
  6. 3.6 Global Injectable Anticoagulants Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Injectable Anticoagulants Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Injectable Anticoagulants Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Injectable Anticoagulants Market by Type
  1. 4.1 Injectable Anticoagulants Type Introduction
  2. 4.1.1 LMWH
  3. 4.1.2 Fibrinolytics
  4. 4.1.3 Unfractionated Heparin
  5. 4.1.4 Others
  6. 4.2 Global Injectable Anticoagulants Sales Value by Type
  7. 4.2.1 Global Injectable Anticoagulants Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Injectable Anticoagulants Sales Value by Type (2021-2032)
  9. 4.2.3 Global Injectable Anticoagulants Sales Value Share by Type (2021-2032)
5 Injectable Anticoagulants Market by Application
  1. 5.1 Injectable Anticoagulants Application Introduction
  2. 5.1.1 ACS/MI
  3. 5.1.2 VTE
  4. 5.1.3 AF
  5. 5.1.4 Others
  6. 5.2 Global Injectable Anticoagulants Sales Value by Application
  7. 5.2.1 Global Injectable Anticoagulants Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Injectable Anticoagulants Sales Value by Application (2021-2032)
  9. 5.2.3 Global Injectable Anticoagulants Sales Value Share by Application (2021-2032)
6 Injectable Anticoagulants Regional Value Analysis
  1. 6.1 Global Injectable Anticoagulants Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Injectable Anticoagulants Sales Value by Region (2021-2032)
  3. 6.2.1 Global Injectable Anticoagulants Sales Value by Region: 2021-2026
  4. 6.2.2 Global Injectable Anticoagulants Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Injectable Anticoagulants Sales Value (2021-2032)
  7. 6.3.2 North America Injectable Anticoagulants Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Injectable Anticoagulants Sales Value (2021-2032)
  10. 6.4.2 Europe Injectable Anticoagulants Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Injectable Anticoagulants Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Injectable Anticoagulants Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Injectable Anticoagulants Sales Value (2021-2032)
  16. 6.6.2 South America Injectable Anticoagulants Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Injectable Anticoagulants Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Injectable Anticoagulants Sales Value Share by Country, 2025 VS 2032
7 Injectable Anticoagulants Country-level Value Analysis
  1. 7.1 Global Injectable Anticoagulants Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Injectable Anticoagulants Sales Value by Country (2021-2032)
  3. 7.2.1 Global Injectable Anticoagulants Sales Value by Country (2021-2026)
  4. 7.2.2 Global Injectable Anticoagulants Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Injectable Anticoagulants Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Injectable Anticoagulants Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Injectable Anticoagulants Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Injectable Anticoagulants Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Injectable Anticoagulants Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 King-friend
  8. 8.2.1 King-friend Company Information
  9. 8.2.2 King-friend Business Overview
  10. 8.2.3 King-friend Injectable Anticoagulants Revenue and Gross Margin (2021-2026)
  11. 8.2.4 King-friend Injectable Anticoagulants Product Portfolio
  12. 8.2.5 King-friend Recent Developments
  13. 8.3 Pfizer
  14. 8.3.1 Pfizer Company Information
  15. 8.3.2 Pfizer Business Overview
  16. 8.3.3 Pfizer Injectable Anticoagulants Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Injectable Anticoagulants Product Portfolio
  18. 8.3.5 Pfizer Recent Developments
  19. 8.4 Hepalink
  20. 8.4.1 Hepalink Company Information
  21. 8.4.2 Hepalink Business Overview
  22. 8.4.3 Hepalink Injectable Anticoagulants Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Hepalink Injectable Anticoagulants Product Portfolio
  24. 8.4.5 Hepalink Recent Developments
  25. 8.5 CSBIO
  26. 8.5.1 CSBIO Company Information
  27. 8.5.2 CSBIO Business Overview
  28. 8.5.3 CSBIO Injectable Anticoagulants Revenue and Gross Margin (2021-2026)
  29. 8.5.4 CSBIO Injectable Anticoagulants Product Portfolio
  30. 8.5.5 CSBIO Recent Developments
  31. 8.6 Genentech (Roche)
  32. 8.6.1 Genentech (Roche) Company Information
  33. 8.6.2 Genentech (Roche) Business Overview
  34. 8.6.3 Genentech (Roche) Injectable Anticoagulants Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Genentech (Roche) Injectable Anticoagulants Product Portfolio
  36. 8.6.5 Genentech (Roche) Recent Developments
  37. 8.7 Boehringer Ingelheim
  38. 8.7.1 Boehringer Ingelheim Company Information
  39. 8.7.2 Boehringer Ingelheim Business Overview
  40. 8.7.3 Boehringer Ingelheim Injectable Anticoagulants Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Boehringer Ingelheim Injectable Anticoagulants Product Portfolio
  42. 8.7.5 Boehringer Ingelheim Recent Developments
  43. 8.8 Aspen
  44. 8.8.1 Aspen Company Information
  45. 8.8.2 Aspen Business Overview
  46. 8.8.3 Aspen Injectable Anticoagulants Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Aspen Injectable Anticoagulants Product Portfolio
  48. 8.8.5 Aspen Recent Developments
  49. 8.9 Amphastar Pharmaceuticals
  50. 8.9.1 Amphastar Pharmaceuticals Company Information
  51. 8.9.2 Amphastar Pharmaceuticals Business Overview
  52. 8.9.3 Amphastar Pharmaceuticals Injectable Anticoagulants Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Amphastar Pharmaceuticals Injectable Anticoagulants Product Portfolio
  54. 8.9.5 Amphastar Pharmaceuticals Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst